Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-masked study of ABP 938 vs aflibercept in neovascular age-related macular degeneration
jRCT2080225133Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of 9MW0813 in exudative macular degeneration (3 arms), sponsored by Amgen. Started Mar 2020; status: completed.
02
Drugs
9MW0813
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2080225133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225133.